Daiichi Sankyo Moves Six Disease Programs To India For Discovery
This article was originally published in PharmAsia News
Daiichi Sankyo has moved six drug-discovery programs, those dealing with infectious and inflammatory diseases, to its R&D hub in India
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.